Quantcast

Latest Vaccination Stories

2014-02-18 04:21:13

New VPs of R&D and Clinical Development add extensive pharmaceutical and biotech immunotherapy product development experience BLUE BELL, Pa., Feb. 18, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has expanded its senior management team with two appointments to help advance the company's growing pipeline of preclinical and clinical DNA vaccines. Inovio has appointed Dr. Laurent Humeau as Vice President of R&D and Dr. Jan Marie-Albert Van...

2014-02-12 12:30:03

WORCESTER, Mass. and TORONTO, Feb. 12, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (GNBT) today announced that recent results from a Phase II study of a novel cancer vaccine designed to prevent relapse in patients who have had breast cancer corroborate prior results from an interim analysis conducted in October of 2011. The Company plans to disclose full results from the Phase II clinical trial at this year's American Society of Clinical Oncology (ASCO)...

2014-02-12 08:29:58

ST. PAUL, Minn., Feb. 12, 2014 /PRNewswire-USNewswire/ -- Four leading national medical associations -- the American Academy of Family Physicians (AAFP), the American Academy of Pediatrics (AAP), the American College of Physicians (ACP), and American College of Obstetricians and Gynecologists (ACOG) -- together with the Immunization Action Coalition and the Centers for Disease Control and Prevention, have issued a call urging physicians across the U.S. to educate their patients about...

2014-02-11 04:22:09

2014 Marks A Transformative Year for the Leader in DNA Vaccines and Cancer Immunotherapies BLUE BELL, Pa., Feb. 11, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it has been invited by the New York Stock Exchange to ring the Opening Bell(®) tomorrow, February 12(th), to mark the beginning of an exciting year for the company in which it will reveal all-important phase II efficacy and immune response data for its lead cancer immunotherapy;...

2014-02-10 08:26:48

Report Outlines Recommendations to Overcome Barriers and Support Cancer Prevention Efforts WASHINGTON, Feb. 10, 2014 /PRNewswire-USNewswire/ -- Achieving widespread HPV (human papillomavirus) vaccination is one of the most profound opportunities for cancer prevention, according to a report released today by the President's Cancer Panel. The Panel's report, Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer, issues an urgent call for energizing efforts to reach the HPV...

2014-02-08 08:20:29

Money to support final push for polio eradication GENEVA, Feb. 8, 2014 /PRNewswire-USNewswire/ -- Buoyed by progress made in two of three countries where polio has never been stopped and India's recent success marking three years polio-free, the Lawrence Ellison Foundation announced a planned gift of US$100 million over five years to support global polio eradication. Roughly $20 million of that contribution was delivered in 2013. The donation will help fund the Global Polio...

2014-02-06 16:27:13

Tens of Thousands Die Annually from Vaccine-preventable Diseases WASHINGTON, Feb. 6, 2014 /PRNewswire-USNewswire/ -- Today, the U.S. Centers for Disease Control and Prevention (CDC) released new adult immunization rates for six vaccines recommended for American adults, finding rates fall far below national goals. While some rates improved slightly from 2011 to 2012, rates continued to be as low as: (Logo: http://photos.prnewswire.com/prnh/20100204/TFAHLOGO) -- Only 14 percent of...

2014-02-06 08:28:58

BETHESDA, Md., Feb. 6, 2014 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Linda F. Powers, CEO, will present at the BIO CEO and Investor Conference 2014, which is being held in New York on February 10-11, 2014. NW Bio's presentation will take place on Monday, February 10, at 11:30 a.m. EST in the Basildon Room at the Waldorf-Astoria in New York...

2014-02-05 23:28:52

National Law Firm Settles Flu Vaccine Injury Petition under the National Vaccine Injury Compensation Program. Many are not aware of Compensation Program and the short, strict deadlines that must be met in order to qualify. Wellesley Hills, MA (PRWEB) February 05, 2014 Gold law Firm, LLC recently obtained a large settlement for a 92-year old woman who had a severe reaction to the Influenza Vaccine resulting in Guillain-Barre' Syndrom (“GBS”) . The case, filed in the Court of...

2014-02-05 12:29:15

The feat bolsters rational vaccine design approach that could also be applied to other challenging viruses including HIV and influenza LA JOLLA, Calif., Feb. 5, 2014 /PRNewswire-USNewswire/ -- Scientists at The Scripps Research Institute (TSRI) have invented a new method for designing artificial proteins, and have used it to make key ingredients for a candidate vaccine against a dangerous virus, respiratory syncytial virus (RSV), a significant cause of infant mortality. The virus has...


Latest Vaccination Reference Libraries

0_ac8af9115d7f37daaaa2af4dba273fb1
2011-01-11 14:17:29

The Cowpox virus causes a skin disease known as cowpox. It is related to the vaccinia virus and gained its name because it spread by dairymaids touching the udders of infected cows. It manifests as red blisters. It is similar to smallpox although much milder and was actually the basis of the first smallpox vaccine. A person who recovers from cowpox is immune to smallpox. In 1980 the World Health Organization announced that smallpox was the first disease to be eradicated world wide by a...

More Articles (1 articles) »
Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.